



IMPORTANT INFORMATION

**FOR WOMEN
CONSIDERING
BREAST
IMPLANTS**



COMMON COMPLICATIONS

What are the most common local complications and adverse outcomes with breast implants?

The most common local complications and adverse outcomes associated with breast implants are capsular contracture, reoperation, implant removal, and rupture or deflation of the implant.

Capsular Contracture

After your breast implant surgery, your breasts will begin to heal and adapt to the presence of the breast implants. A regular part of this process is that the breast tissue typically forms an internal scar immediately surrounding the implant. In many cases, this tissue forms a capsule that helps hold the implant in place. However, in some women, the scar tissue around the implant tightens and squeezes the implant. When scar tissue squeezes an implant, it is called capsular contracture.

Capsular contracture causes the breast to feel abnormally firm and can cause pain. There is a scale for describing the severity of the contracture. It is called the Baker Grading Scale. The grades are:

Grade I	Grade II	Grade III	Grade IV
Contracture is observed, but the breast feels and looks normal (it is soft)	The breast is a little firm, but looks normal	The breast is firm and looks abnormal	The breast is hard, painful, and looks abnormal

Capsular contracture may be more common if you have had a breast infection, hematoma (a solid swelling of clotted blood within the tissue) or seroma (collection of fluid that builds up under the surface of your skin). The chances of having contracture typically increase the longer you have your implants. Capsular contracture is a risk factor for implant rupture, and it is one of the most common reasons for reoperation. It also seems that women who have additional surgery to replace their implants (revision surgery) are more likely to have capsular contracture than women having their first augmentation or reconstruction.

Reoperation

It is likely that you will need additional surgery (a reoperation) at some point after your first breast implant surgery, either to correct a problem with or replace your breast implants. Patients may decide to change the size or type of their breast implants, requiring additional surgery. Problems such as rupture, capsular contracture, asymmetry (lack of proportion of shape, size and/or position between the two breasts), hypertrophic scarring (irregular, raised scar), infection, and shifting can require additional surgery. Some changes to your breast(s) after having breast implants are irreversible (cannot be changed or fixed). These may include dimpling, puckering, wrinkling, or the appearance that the breast is empty or deflated.

Implant Removal

Your breast implants may be removed (with or without being replaced) at some point during the course of



your life. You and your doctor may decide to remove an implant or implants because of a complication or to improve the cosmetic result. Because these are not lifetime devices, the longer you have your breast implants, the more likely it will be for you to have them removed for any reason, either because of dissatisfaction, an unacceptable cosmetic result, or a complication such as severe capsular contracture.

Rupture

Breast implants are considered to have ruptured when the implant shell develops a tear or hole. Implants could rupture any time after your implant surgery, but the longer the implants are in place, the higher the possibility that the implants will rupture or the gel will leak. Breast implants may rupture or leak because of any of these reasons:

- Damage by surgical instruments at the time of implantation or during any subsequent surgical procedure,
- Stress to the implant during implant surgery that weakens it,
- Folding or wrinkling of the implant shell,
- Excessive force to the chest (for example, during closed capsulotomy, which is a procedure that should not be used),
- Trauma (like being in a car accident),
- Compression during a mammogram,
- Severe capsular contracture, or
- Normal use over time.

Additional information, the most common local complications, and adverse outcomes with breast implants can be found at: <https://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/ImplantsandProsthetics/BreastImplants/ucm259296.htm>

BREAST-IMPLANT ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA (BIA-ALCL)

What is BIA-ALCL?

Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL) is an uncommon type of lymphoma that has been found in women with breast implants.^(1-3, 8) It usually appears as a swelling of the breast caused by fluid surrounding the implant, usually occurring at least one year after surgery.⁽⁴⁾ Other late onset symptoms may include pain, lumps, swelling, or asymmetry.⁽¹⁾ The recommended treatment is the removal of the breast implant and the surrounding tissue; treatment has been successful when caught early.^(4, 5)

How often does BIA-ALCL occur?

Health authorities globally state the incidence of BIA-ALCL is uncommon.^(1-3, 8)

The FDA has noted that "BIA-ALCL occurs more frequently following implantation of breast implants with textured surfaces."⁽¹⁾

Mentor continues to work with industry groups, physician scientists and health authorities globally to better understand the associated risks and causes of BIA-ALCL. At Mentor we put patient safety as our number one priority,⁽⁶⁾ Mentor continues to closely monitor reports of and information about BIA-ALCL.

Where can I find additional resources about BIA-ALCL?

The U.S. Food and Drug Administration (FDA),^(7, 8) French: National Security Agency of Medicines and Health Products (ANSM),⁽⁹⁾ Australian Therapeutic Goods Administration (TGA)⁽¹⁰⁾ Medicines & Healthcare products Regulatory Agency (MHRA),⁽¹¹⁾ The American Society of Plastic Surgeons (ASPS),⁽¹¹⁾ The American Society for Aesthetic Plastic Surgery (ASAPS),⁽¹⁵⁾ The Plastic Surgery Foundation (PSF)⁽¹⁴⁾ and the International Society of Aesthetic and Plastic Surgery (ISAPS)⁽¹⁵⁾ all provide up to date resources about the risks and benefits of breast implant surgery as well as information about BIA-ALCL.

What should I do if I already have breast implants?

The FDA does not recommend changes to your routine medical care and follow-up, nor does it recommend the removal of implants.^(1-2, 8) Health authorities state that BIA-ALCL is uncommon; it has occurred in only a very small number of the millions of women who have breast implants.^(1-3, 8)

The FDA notes that symptoms of BIA-ALCL are typically late onset, meaning they occur at least one year after your surgery. Symptoms typically include pain, lumps, swelling, or asymmetry. If you experience any of these symptoms, contact your health care provider promptly to schedule an appointment.⁽⁵⁾

Although not specific to BIA-ALCL, the FDA recommends that you follow standard medical recommendations including:^(1-2, 8)

- Monitor your breast implants. If you notice any changes, contact your health care provider promptly to schedule an

appointment. For more information on self breast exams, visit MedlinePlus: Breast Self Exam at: <https://medlineplus.gov/ency/article/001993.htm>.⁽¹⁶⁾

- Get routine mammography screening.
- If you have silicone gel-filled breast implants, get periodic magnetic resonance imaging (MRI) to detect ruptures as recommended by your health care provider. The FDA-approved product labeling for silicone gel-filled breast implants states that the first MRI should occur three years after implant surgery and every two years thereafter.

CHOICE OF IMPLANTS

Why should I consider textured implants?

Textured implants have certain advantages over smooth implants. The newest generation of shaped breast implants are textured to reduce movement of the implant. Textured implants have other benefits in reducing complications, which may require reoperation, that occur much more frequently than BIA-ALCL, including capsular contracture.^(17, 18) Selection of the most appropriate implant for you should be a conversation between you and your doctor.



Are Mentor implants safe?

MENTOR® Breast Implants are backed by substantial clinical data demonstrating safety and effectiveness in both augmentation and reconstruction, including 10-year clinical trials.⁽¹⁷⁻²²⁾ The evidence continues to support the safe and effective use of MENTOR® Breast Implants in breast surgery.

Individuals who have been implanted with textured breast implants may, at some point during their clinical history, have a risk of developing BIA-ALCL. While textured breast implants have established clinical benefits, leading researchers recommend that clinicians should consider the relative risk of developing BIA-ALCL when selecting a textured implant for their patient; clinical need should be adequately justified when selecting higher surface area implants like Biocell and Polyurethane. Current literature concludes that the risk of developing BIA-ALCL differs between different textured devices and has been shown to be rare with Mentor breast implants.^(8, 23-30)

BREAST IMPLANT ILLNESS

Breast Implant Illness is a general term describing a broad range of signs and symptoms that are under consideration for being associated with breast implants. Scientific studies do not support claims that silicone gel breast implants cause systemic illness.

For more information about the inherent risks associated with breast implants, please speak with your surgeon and review the Product Insert Data Sheets and patient brochures that your surgeon provides to you.

REFERENCES

1. Anaplastic Large Cell Lymphoma (ALCL) In Women with Breast Implants: Preliminary FDA Findings and Analyses: Center for Devices and Radiological Health, U.S. Food and Drug Administration; January 2011 [cited 2021 28 June].
2. Lymphome Anaplasique à Grandes Cellules associé aux implants mammaires (LAGC-AIM): Point sur les investigations en cours- Point d'Information: L'Agence nationale de sécurité du médicament et des produits de santé (ANSM). 06 July 2016 [cited 2021 28 June].
3. Breast Implants: Expert Advisory Panel Advice on Association with Anaplastic Large Cell Lymphoma: Australian Government Department of Health Therapeutic Goods Administration; 20 December 2016 [cited 2021 28 June].
4. Clemens MW, Medeiros LJ, Butler CE, Hunt KK, Fanale MA, Horwitz S, et al. Complete Surgical Excision Is Essential for the Management of Patients With Breast Implant-Associated Anaplastic Large-Cell Lymphoma. *J Clin Oncol*. 2016;34(2):160-8. Epub 2015/12/03. doi: 10.1200/jco.2015.63.3412. PubMed PMID: 26628470; PubMed Central PMCID: PMC4872006 online at <http://www.jco.org>. Author contributions are found at the end of this article.
5. Clemens MW, Horwitz SM. NCCN Consensus Guidelines for the Diagnosis and Management of Breast Implant-Associated Anaplastic Large Cell Lymphoma. *Aesthetic surgery journal*. 2017. Epub 2017/02/12. doi: 10.1093/asj/sjw259. PubMed PMID: 28184418.
6. Mentor Worldwide LLC. FDA Customer Letter_Final Mentor Worldwide LLC. TX820_130420_01.
7. US Food and Drug Administration (FDA) 2021. Available from: <https://www.fda.gov/medical-devices/letters-health-care-providers/breast-implant-associated-anaplastic-large-cell-lymphoma-bia-alc-letter-health-care-providers>
8. Questions and Answers about Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL), 2019 Available from: <https://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/ImplantsandProsthetics/BreastImplants/ucm239995.htm> [accessed 28 June 2021].
9. National Security Agency of Medicines and Health Products (ANSM). Available from: <https://ansm.sante.fr/> [accessed 28 June 2021].
10. Australian Therapeutic Goods Administration (TGA) Available from: <https://www.tga.gov.au/> [accessed 28 June 2021].
11. UK Medicines & Healthcare products Regulatory Agency (MHRA). Available from: <https://www.gov.uk/government/organisations/medicines-and-healthcare-products-regulatory-agency> [accessed 28 June 2021].
12. The American Society of Plastic Surgeons (ASPS) Available from: <https://www.plasticsurgery.org/> [accessed 28 June 2021].
13. American Society for Aesthetic Plastic Surgery (ASAPS). Available from: <https://www.plasticsurgery.org/> [accessed 28 June 2021].
14. Plastic Surgery Foundation (PSF). Available from: <https://www.thepsf.org/>
15. International Society of Aesthetic and Plastic Surgery (ISAPS). Available from: <https://www.isaps.org/> [accessed 28 June 2021].
16. MedlinePlus. Breast self-exam. Available from: <https://medlineplus.gov/ency/article/001993.htm> [accessed 28 June 2021].
17. Summary of the Safety and Effectiveness of Mentor's MemoryShape™ Mammory Prosthesis in Subjects Who are Undergoing Primary Breast Augmentation, Primary Breast Reconstruction, or Revision. 10-Year Core Gel Clinical Study Final Report. November 2012. MemoryShape Post- Approval Cohort Study (formerly Contour Profile Gel Core Study). June 2014.
18. Summary of the Safety and Effectiveness of Mentor's MemoryGel Silicone Gel-Filled Implants in Patients Who are Undergoing Primary Breast Augmentation, Primary Breast Reconstruction, or Revision. 10-Year Core Gel Clinical Study Final Report. November 2012.
19. Mentor MemoryShape Post-Approval Continued Access Study (formerly Contour Profile Gel Continued Access Study), Final Report. October 2014.
20. Mentor MemoryGel Breast Implant Large Post Approval Study Re-Op Phase Annual Report. 17 June 2016.
21. Adjunct Study Final Report for Mentor's MemoryGel Silicone Gel-filled Breast Implants. 02 November 2012.
22. Mentor MemoryShape CPG Styles Study: A Study of the Safety of the Contour Profile Gel Breast Implants in Subjects who are Undergoing Primary Breast Augmentation, Primary Breast Reconstruction, or Revision, Final Clinical Study Report. 20 October 2015.
23. de Boer, M., et al. Breast implants and the risk of anaplastic large-cell lymphoma in the breast. *JAMA Oncology*, 2018. 4(3): p. 335-341.
24. Brody, GS., et al. Anaplastic Large Cell Lymphoma Occurring in Women with Breast Implants: Analysis of 173 Cases. *Plastic and Reconstructive Surgery*, 2015. 135(3): p. 695-705.
25. Gidengil, CA., et al. Breast Implant-Associated Anaplastic Large Cell Lymphoma: A Systematic Review. *Plastic and Reconstructive Surgery*, 2015. 135(3): p. 713-720.
26. Loch-Wilkinson, A., et al. Breast implant associated Anaplastic Large Cell Lymphoma in Australia and New Zealand - high surface area textured implants are associated with increased risk. *Plastic and Reconstructive Surgery*, 2017. 140(4): p. 645-654.
27. Doren, E.L., et al. U.S. Epidemiology of Breast Implant-Associated Anaplastic Large Cell Lymphoma. *Plastic and Reconstructive Surgery*, 2017. 139(5): p. 1042-1050.
28. Srinivasa, D.R., et al. Global Adverse Event Reports of Breast Implant-Associated ALCL: An International Review of 40 Government Authority Databases. *Plast Reconstr Surg*, 2017. 139(5): p. 1029-1039.
29. Johnson, L., et al. Breast implant associated anaplastic large cell lymphoma: The UK experience. Recommendations on its management and implications for informed consent. *Eur J Surg Oncol*, 2017. 43(8): p. 1393-1401.
30. Deva, A.K. "BIA-ALCL: Translating Science Into Practice." The Aesthetic Meeting of ASAPS, April 29, 2018, Javits Center, New York, NY. Lecture in Panel: Hot Topics in Breast Surgery—ALCL, Texture, Biofilms.

IMPORTANT SAFETY INFORMATION

The MENTOR® Collection of Breast Implants are indicated for breast reconstruction and breast augmentation - in women who are at least 18 years old for MENTOR® MemoryGel® Breast Implants, MENTOR® CPG™ Breast Implants, or MENTOR® Saline Breast Implants. Breast implant surgery should not be performed in women:

- With active infection anywhere in their body
- With existing cancer or pre-cancer of their breast who have not received adequate treatment for those conditions
- Who are currently pregnant or nursing

Safety and effectiveness have not been established in patients with autoimmune diseases (for example lupus and scleroderma), a weakened immune system, conditions that interfere with wound healing and blood clotting, or reduced blood supply to breast tissue. Patients with a diagnosis of depression, or other mental health disorders, should wait until resolution or stabilization of these conditions prior to undergoing breast implantation surgery.

There are risks associated with breast implant surgery. You should be aware that breast implants are not lifetime devices and breast implantation may not be a one-time surgery. The chance of developing complications increases over time. You may need additional unplanned surgeries on your breasts because of complications or unacceptable cosmetic outcomes. Many of the changes to your breast following implantation are irreversible (cannot be undone) and breast implants may affect your ability to breastfeed, either by reducing or eliminating milk production.

Breast implants are not lifetime devices and breast implantation may not be a one-time surgery. The most common complications for breast augmentation with MemoryGel® Implants include any reoperation, capsular contracture, nipple sensation changes, and implant removal with or without replacement. The most common complications with CPG™ Breast Implants for breast augmentation include reoperation for any reason, implant removal with or without replacement, and ptosis. A lower risk of complication is rupture. The health consequences of a ruptured silicone gel breast implant have not been fully established. MRI screenings are recommended three years after initial implant surgery and then every two years after to detect silent rupture. Breast implants are also associated with the risk of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL), an uncommon type of lymphoma. An individual's risk of developing BIA-ALCL with MENTOR® Breast Implants is low based on the data currently available on the incidence of worldwide cases.

Detailed information regarding the risks and benefits associated with MENTOR® Breast Implants is provided in several educational brochures, including the 'Important Information for Woman Considering Breast Implants' brochure, and the 'Making an Informed Decision' brochure. These brochures are available from your surgeon or visit <https://breastimplantsbymentor.net/safety/mentor-safety>. It is important that you read and understand these brochures when considering MENTOR® Breast Implants. MENTOR® CONTOUR PROFILE™ Breast Tissue Expanders are used for breast reconstruction after mastectomy, correction of an underdeveloped breast, scar revision, and tissue defect procedures. These expanders are intended for temporary subcutaneous or submuscular implantation; they should be used within a time frame determined by the physician to achieve the clinically desired degree of tissue expansion.

DO NOT use the MENTOR® CONTOUR PROFILE™ Tissue Expander in patients that have a previously implanted device such as pacemakers, drug infusion devices, artificial sensing devices, etc. that could be affected by a magnetic field. Mentor has not tested the effects of radiation therapy with the MENTOR® CONTOUR PROFILE™ Expander devices. The incidence of extrusion of the expander has been shown to increase when the expander has been placed in injured areas: scarred, heavily irradiated or burned tissue, crushed bone areas, where severe surgical reduction of the area has previously been performed; and where steroids are used in the surgical pocket. Detailed information about indications, contraindications, warnings, and precautions associated with the use of MENTOR® CONTOUR PROFILE™ Expanders are provided in the Instructions for Use (IFU) available online at www.mentorwllc.eu



33 Technology Drive
Irvine, CA 92618 USA
© Mentor Worldwide LLC 2021
178137-210526 EMEA 2021

(805) 879-6000
Customer Service: (800) 235-5731 Fax: (805) 967-7108
www.mentorwllc.com